| 摘要 |
FIELD: chemico-pharmaceutical industry. ^ SUBSTANCE: the present innovation deals with applying receptor NK-1 antagonist, not obligatory in combination with magnesium salt, for treating and/or preventing craniocerebral and spinal trauma or nervous tissue lesion, where receptor NK-1 antagonist is being a compound of general formula , where R, R1, R2, R2', R3, R4 have values mentioned in the description of the present innovation, its pharmaceutically acceptable acid-additive salts, either separately or in combination with magnesium salt. The example is the application of 2-(3.5-bis-trifluoromethylphenyl)-N-methyl-N-(6-morpholine-4-yl-4-ortho-tolylpyridine-3-yl)isobutyramide. ^ EFFECT: higher efficiency of therapy. ^ 8 cl, 3 dwg |
